AI and organoid platforms for brain-targeted theranostics

Area of Science:

• Neuroscience
• Biotechnology
• Artificial Intelligence

Background:

• Developing therapies for complex brain diseases is challenging due to biological complexity and the blood-brain barrier.
• Traditional research and development (R&D) for nanomedicines is inefficient.

Purpose of the Study:

• Introduce an intelligent theranostic paradigm to accelerate nanomedicine development for brain diseases.
• Integrate high-fidelity brain organoid models, high-throughput screening (HTS/HCS), and Artificial Intelligence (AI).

Main Methods:

• Utilize brain organoid platforms for diagnostic data generation on nanomedicine performance.
• Employ AI to process organoid data for therapeutic guidance.
• Implement a closed-loop workflow for rational drug design, synthesis, and interaction prediction.

Main Results:

• The proposed paradigm enables AI-driven convergence for nanomedicine development.
• Predictive data from organoids guides AI in therapeutic strategy.
• Accelerated development of precisely targeted and individualized nanomedicines is anticipated.

Conclusions:

• The AI-driven theranostic paradigm offers a novel approach to overcome R&D inefficiencies.
• This integrated workflow promises significant acceleration in developing effective nanomedicines for brain diseases.
• This approach provides new hope for treating complex neurological disorders.